2.55
0.07 (2.82%)
| Penutupan Terdahulu | 2.48 |
| Jumlah Dagangan | 38,816 |
| Harga / Buku (P/B) | 2.20 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.640 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.81% |
| Nisbah Semasa (MRQ) | 5.33 |
| Aliran Tunai Operasi (OCF TTM) | -15.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.86 M |
| Pulangan Atas Aset (ROA TTM) | -57.49% |
| Pulangan Atas Ekuiti (ROE TTM) | -112.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Chemomab Therapeutics Ltd. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.5 |
| Purata | 0.17 |
|
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 15.27% |
| % Dimiliki oleh Institusi | 16.93% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Adar1 Capital Management, Llc | 30 Jun 2026 | 80,000 |
| Kestra Private Wealth Services, Llc | 30 Jun 2026 | 61,710 |
| Ikarian Capital, Llc | 30 Jun 2026 | 51,793 |
| Philadelphia Investment Partners, Llc | 30 Jun 2026 | 15,000 |
| Lido Advisors, Llc | 30 Jun 2026 | 14,341 |
| Gamma Investing Llc | 30 Jun 2026 | 4,740 |
| Smartharvest Portfolios, Llc | 30 Jun 2026 | 0 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |